Therapist, clinical pharmacologist Andrei Kondrakhin told Lente.ru that the composition of the preparation of Paxlovid, tested by the American pharmaceutical company Pfizer against COVID-19, is similar to the drug that has already been used against a new coronavirus infection that was originally created for combating human immunodeficiency virus (HIV).
earlier “Vedomosti” reported that Roszdravnadzor issued a Pfizer permission to conduct clinical tests of the drug Paxlovid-inhibitor protease plus a ritonavir designed for the prevention and treatment of COVID-19. According to the developer, the second phase of clinical studies has shown that Paxlovid helped reduce the risk of hospitalization or death from COVID-19 by 89 percent.
“Called Find Differences. We tried to treat at the beginning of a pandemic Ritonavir, was a Caletra drug, which was used to treat AIDS patients, it contains ritonavir and Lopinavir in its composition, which is a HIV-1 protease inhibitor and HIV-2 immunodeficiency virus . That is, they left Ritonavir and added a protease inhibitor, it turns out that this is the repetition of what we have already passed, “the doctor noted.
In Russia, there are enough treatment schemes, according to the latest recommendations against COVID-19, two antiviral drugs are used – Faviupampi and Remidesivir, Kondrakhin said, but positively reacted to the possible market to enter the new product: “It is good that there is a new drug, and It would be nice if we could apply it immediately at the first signs of the disease, but you still need to see how it will behave. “
Russia Along with other countries, the drug Caletra began to use at the beginning of the pandemic, but a number of studies have shown that the tool does not have a favorable effect, wrote a spell. Center, after which the doctors refused to use it in the treatment of COVID-19.